The alpha emitter market size has grown exponentially in recent years. It will grow from $1.61 billion in 2025 to $1.99 billion in 2026 at a compound annual growth rate (CAGR) of 23.6%. The growth in the historic period can be attributed to limited availability of alpha-emitting radionuclides, reliance on natural sources like uranium and radium, growing awareness of targeted cancer therapies, emergence of early clinical trials, limited production infrastructure.
The alpha emitter market size is expected to see exponential growth in the next few years. It will grow to $4.6 billion in 2030 at a compound annual growth rate (CAGR) of 23.3%. The growth in the forecast period can be attributed to development of artificial radionuclide production facilities, rising investment in oncology treatments, increasing adoption in bone metastasis and prostate cancer therapies, advancement in targeted alpha therapy technologies, expanding medical research applications. Major trends in the forecast period include rising adoption of alpha-emitter-based cancer therapies, increased research in radionuclide production and isolation, growth in artificially produced alpha emitters, expansion of therapeutic applications beyond oncology, enhanced focus on safety and regulatory compliance for handling radioactive materials.
The growing prevalence of cancer is expected to drive the growth of the alpha emitter market in the coming years. Cancer is a disease characterized by the uncontrolled proliferation and spread of abnormal cells within the body, which can form tumors and invade surrounding tissues. The increasing prevalence of cancer is influenced by factors such as aging populations, environmental exposure, lifestyle changes, and advancements in detection methods. Alpha emitters are used in cancer therapy to precisely target and destroy tumor cells while minimizing damage to nearby healthy tissues. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2050, there will be more than 35 million new cancer cases worldwide, representing a 77% increase compared with the estimated 20 million cases recorded in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the alpha emitter market.
Companies operating in the alpha-emitter market are investing in innovative solutions, such as alpha-emitting radionuclides produced using cyclotrons, to strengthen their competitive positioning. Alpha-emitting radionuclides generated using cyclotrons are radioactive isotopes that emit alpha particles during decay, produced by accelerating charged particles to high energies within a cyclotron. For example, in April 2023, Ionetix, a US-based cyclotron and technology company, produced its first alpha-emitting radionuclide, Astatine-211 (At-211), at its newly established Alpha Isotope Manufacturing facility in Lansing, Michigan. This facility is notable for being the first in the US dedicated exclusively to producing alpha-emitting radionuclides using cyclotron technology. Production was achieved through the commissioning of a 30 MeV cyclotron designed to accelerate alpha particles for high-yield generation of At-211 and Actinium-225 (Ac-225).
In February 2024, Bristol-Myers Squibb Co. (BMS), a US-based biopharmaceutical company, acquired RayzeBio, Inc. for $4.1 billion. With this acquisition, Bristol-Myers Squibb Co. enhances its oncology portfolio by adding innovative radiopharmaceutical therapies, particularly targeted alpha-emitter treatments. RayzeBio Inc. is a US-based provider of alpha-emitter technologies.
Major companies operating in the alpha emitter market are Bayer AG, Lantheus Holdings Inc., Curium Pharma, Eckert & Ziegler BEBIG GmbH, Telix Pharmaceuticals Limited, NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, International Isotopes Inc., IBA Radiopharma Solutions, Orano Med LLC, Actinium Pharmaceuticals Inc., Clarity Pharmaceuticals Ltd., RadioMedix Inc., Nordic Nanovector ASA, TAE Life Sciences, Fusion Pharmaceuticals Inc., Alpha Tau Medical Ltd., Alpha‑9 Oncology, Aktis Oncology, Abdera Therapeutics, Oncoinvent ASA, Theragnostics Ltd., ARICEUM Therapeutics, Sirius Medical Systems B.V.
North America was the largest region in the alpha emitter market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha emitter market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alpha emitter market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the alpha emitter market by increasing costs for imported radionuclides and production equipment, particularly affecting segments like radium-223, actinium-225, and bismuth-213. Asia-Pacific regions, including China and India, are highly impacted due to import dependencies. While tariffs raise production costs and may slow supply chains, they also incentivize local production, research investment, and development of alternative radionuclide sources, supporting long-term market growth.
The alpha emitter market research report is one of a series of new reports that provides alpha emitter market statistics, including alpha emitter industry global market size, regional shares, competitors with a alpha emitter market share, detailed alpha emitter market segments, market trends and opportunities, and any further data you may need to thrive in the alpha emitter industry. This alpha emitter market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
An alpha emitter is a form of radioactive material that releases alpha particles during radioactive decay. It includes elements such as uranium, radium, and plutonium, which undergo alpha decay as part of natural radioactive processes. Alpha emitters are important in medical treatments, particularly cancer therapy, and have applications in technologies like smoke detectors and space exploration.
The main radionuclides of alpha emitters include radium, actinium, lead, bismuth, and others. Radium is a radioactive substance used in both therapeutic and diagnostic medical procedures. The sources include natural origins, artificially produced sources, and others, while the applications include pancreatic cancer, ovarian cancer, prostate cancer, lymphoma, melanoma, bone metastasis, and others. They are used across various end-users such as hospitals, medical research organizations, and others.
The alpha emitter market consists of sales of Plutonium-238 (Pu-238), Thorium-227 (Th-227), Polonium-210 (Po-210), and Americium-241 (Am-241). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The alpha emitter market size is expected to see exponential growth in the next few years. It will grow to $4.6 billion in 2030 at a compound annual growth rate (CAGR) of 23.3%. The growth in the forecast period can be attributed to development of artificial radionuclide production facilities, rising investment in oncology treatments, increasing adoption in bone metastasis and prostate cancer therapies, advancement in targeted alpha therapy technologies, expanding medical research applications. Major trends in the forecast period include rising adoption of alpha-emitter-based cancer therapies, increased research in radionuclide production and isolation, growth in artificially produced alpha emitters, expansion of therapeutic applications beyond oncology, enhanced focus on safety and regulatory compliance for handling radioactive materials.
The growing prevalence of cancer is expected to drive the growth of the alpha emitter market in the coming years. Cancer is a disease characterized by the uncontrolled proliferation and spread of abnormal cells within the body, which can form tumors and invade surrounding tissues. The increasing prevalence of cancer is influenced by factors such as aging populations, environmental exposure, lifestyle changes, and advancements in detection methods. Alpha emitters are used in cancer therapy to precisely target and destroy tumor cells while minimizing damage to nearby healthy tissues. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2050, there will be more than 35 million new cancer cases worldwide, representing a 77% increase compared with the estimated 20 million cases recorded in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the alpha emitter market.
Companies operating in the alpha-emitter market are investing in innovative solutions, such as alpha-emitting radionuclides produced using cyclotrons, to strengthen their competitive positioning. Alpha-emitting radionuclides generated using cyclotrons are radioactive isotopes that emit alpha particles during decay, produced by accelerating charged particles to high energies within a cyclotron. For example, in April 2023, Ionetix, a US-based cyclotron and technology company, produced its first alpha-emitting radionuclide, Astatine-211 (At-211), at its newly established Alpha Isotope Manufacturing facility in Lansing, Michigan. This facility is notable for being the first in the US dedicated exclusively to producing alpha-emitting radionuclides using cyclotron technology. Production was achieved through the commissioning of a 30 MeV cyclotron designed to accelerate alpha particles for high-yield generation of At-211 and Actinium-225 (Ac-225).
In February 2024, Bristol-Myers Squibb Co. (BMS), a US-based biopharmaceutical company, acquired RayzeBio, Inc. for $4.1 billion. With this acquisition, Bristol-Myers Squibb Co. enhances its oncology portfolio by adding innovative radiopharmaceutical therapies, particularly targeted alpha-emitter treatments. RayzeBio Inc. is a US-based provider of alpha-emitter technologies.
Major companies operating in the alpha emitter market are Bayer AG, Lantheus Holdings Inc., Curium Pharma, Eckert & Ziegler BEBIG GmbH, Telix Pharmaceuticals Limited, NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, International Isotopes Inc., IBA Radiopharma Solutions, Orano Med LLC, Actinium Pharmaceuticals Inc., Clarity Pharmaceuticals Ltd., RadioMedix Inc., Nordic Nanovector ASA, TAE Life Sciences, Fusion Pharmaceuticals Inc., Alpha Tau Medical Ltd., Alpha‑9 Oncology, Aktis Oncology, Abdera Therapeutics, Oncoinvent ASA, Theragnostics Ltd., ARICEUM Therapeutics, Sirius Medical Systems B.V.
North America was the largest region in the alpha emitter market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha emitter market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alpha emitter market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the alpha emitter market by increasing costs for imported radionuclides and production equipment, particularly affecting segments like radium-223, actinium-225, and bismuth-213. Asia-Pacific regions, including China and India, are highly impacted due to import dependencies. While tariffs raise production costs and may slow supply chains, they also incentivize local production, research investment, and development of alternative radionuclide sources, supporting long-term market growth.
The alpha emitter market research report is one of a series of new reports that provides alpha emitter market statistics, including alpha emitter industry global market size, regional shares, competitors with a alpha emitter market share, detailed alpha emitter market segments, market trends and opportunities, and any further data you may need to thrive in the alpha emitter industry. This alpha emitter market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
An alpha emitter is a form of radioactive material that releases alpha particles during radioactive decay. It includes elements such as uranium, radium, and plutonium, which undergo alpha decay as part of natural radioactive processes. Alpha emitters are important in medical treatments, particularly cancer therapy, and have applications in technologies like smoke detectors and space exploration.
The main radionuclides of alpha emitters include radium, actinium, lead, bismuth, and others. Radium is a radioactive substance used in both therapeutic and diagnostic medical procedures. The sources include natural origins, artificially produced sources, and others, while the applications include pancreatic cancer, ovarian cancer, prostate cancer, lymphoma, melanoma, bone metastasis, and others. They are used across various end-users such as hospitals, medical research organizations, and others.
The alpha emitter market consists of sales of Plutonium-238 (Pu-238), Thorium-227 (Th-227), Polonium-210 (Po-210), and Americium-241 (Am-241). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Alpha Emitter Market Characteristics
3. Alpha Emitter Market Supply Chain Analysis
4. Global Alpha Emitter Market Trends and Strategies
5. Alpha Emitter Market Analysis of End Use Industries
7. Global Alpha Emitter Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Alpha Emitter Total Addressable Market (TAM) Analysis for the Market
9. Alpha Emitter Market Segmentation
10. Alpha Emitter Market Regional and Country Analysis
11. Asia-Pacific Alpha Emitter Market
12. China Alpha Emitter Market
13. India Alpha Emitter Market
14. Japan Alpha Emitter Market
15. Australia Alpha Emitter Market
16. Indonesia Alpha Emitter Market
17. South Korea Alpha Emitter Market
18. Taiwan Alpha Emitter Market
19. South East Asia Alpha Emitter Market
20. Western Europe Alpha Emitter Market
21. UK Alpha Emitter Market
22. Germany Alpha Emitter Market
23. France Alpha Emitter Market
24. Italy Alpha Emitter Market
25. Spain Alpha Emitter Market
26. Eastern Europe Alpha Emitter Market
27. Russia Alpha Emitter Market
28. North America Alpha Emitter Market
29. USA Alpha Emitter Market
30. Canada Alpha Emitter Market
31. South America Alpha Emitter Market
32. Brazil Alpha Emitter Market
33. Middle East Alpha Emitter Market
34. Africa Alpha Emitter Market
36. Alpha Emitter Market Competitive Landscape and Company Profiles
37. Alpha Emitter Market Other Major and Innovative Companies
40. Alpha Emitter Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Alpha Emitter Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses alpha emitter market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for alpha emitter? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The alpha emitter market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type Of Radionuclide: Radium; Actinium; Lead; Bismuth; Other Types Of Radionuclides2) By Source: Natural Sources; Artificially Produced Sources; Other Sources
3) By Application: Pancreatic Cancer; Ovarian Cancer; Prostate Cancer; Lymphoma; Melanoma; Bone Metastasis; Other Applications
4) By End-User: Hospitals; Medical Research Institutions; Other End-Users
Subsegments:
1) By Radium: Radium-223; Radium-226; Radium-2282) By Actinium: Actinium-227; Actinium-225
3) By Lead: Lead-210; Lead-212
4) By Bismuth: Bismuth-213; Bismuth-212
5) By Other Types of Radionuclides: Thorium; Polonium; Francium
Companies Mentioned: Bayer AG; Lantheus Holdings Inc.; Curium Pharma; Eckert & Ziegler BEBIG GmbH; Telix Pharmaceuticals Limited; NorthStar Medical Radioisotopes LLC; ITM Isotope Technologies Munich SE; International Isotopes Inc.; IBA Radiopharma Solutions; Orano Med LLC; Actinium Pharmaceuticals Inc.; Clarity Pharmaceuticals Ltd.; RadioMedix Inc.; Nordic Nanovector ASA; TAE Life Sciences; Fusion Pharmaceuticals Inc.; Alpha Tau Medical Ltd.; Alpha‑9 Oncology; Aktis Oncology; Abdera Therapeutics; Oncoinvent ASA; Theragnostics Ltd.; ARICEUM Therapeutics; Sirius Medical Systems B.V.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Alpha Emitter market report include:- Bayer AG
- Lantheus Holdings Inc.
- Curium Pharma
- Eckert & Ziegler BEBIG GmbH
- Telix Pharmaceuticals Limited
- NorthStar Medical Radioisotopes LLC
- ITM Isotope Technologies Munich SE
- International Isotopes Inc.
- IBA Radiopharma Solutions
- Orano Med LLC
- Actinium Pharmaceuticals Inc.
- Clarity Pharmaceuticals Ltd.
- RadioMedix Inc.
- Nordic Nanovector ASA
- TAE Life Sciences
- Fusion Pharmaceuticals Inc.
- Alpha Tau Medical Ltd.
- Alpha‑9 Oncology
- Aktis Oncology
- Abdera Therapeutics
- Oncoinvent ASA
- Theragnostics Ltd.
- ARICEUM Therapeutics
- Sirius Medical Systems B.V.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.99 Billion |
| Forecasted Market Value ( USD | $ 4.6 Billion |
| Compound Annual Growth Rate | 23.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
